In Vitro Efficacy of Polysaccharide-Based Nanoparticles Containing Disease-Modifying Antirheumatic Drugs

[1] Lindholm A(1993)Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 205-18

[2] Kahan BD(1988)Methotrexate in rheumatoid arthritis J Am Acad Dermatol 19 126-8

[3] Weinblatt ME(2003)Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus Immunol Cell Biol 81 350-3

[4] Kremer JM(1994)Methotrexate: adverse reactions and major toxicities Rheum Dis Clin N Am 20 513-28

[5] Mottram PL(2007)Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs Dermatol Clin 25 195-205

[6] Goodman TA(2012)The multiple facets of glucocorticoid action in rheumatoid arthritis Nat Rev Rheumatol 8 645-55

[7] Polisson RP(2008)Polysaccharides-based nanoparticles as drug delivery systems Adv Drug Deliv Rev 60 1650-62

[8] Wolverton SE(2005)Chitosan-based particles as controlled drug delivery systems Drug Deliv 12 41-57

[9] Remlinger K(2002)Preparation and characterization of chitosan microparticles intended for controlled drug delivery Int J Pharm 249 165-74

[10] Baschant U(2001)Chitosan nanoparticles as delivery systems for doxorubicin J Control Release 73 255-67

[1] Lindholm A(1993)Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 205-18

[2] Kahan BD(1988)Methotrexate in rheumatoid arthritis J Am Acad Dermatol 19 126-8

[3] Weinblatt ME(2003)Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus Immunol Cell Biol 81 350-3

[4] Kremer JM(1994)Methotrexate: adverse reactions and major toxicities Rheum Dis Clin N Am 20 513-28

[5] Mottram PL(2007)Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs Dermatol Clin 25 195-205

[6] Goodman TA(2012)The multiple facets of glucocorticoid action in rheumatoid arthritis Nat Rev Rheumatol 8 645-55

[7] Polisson RP(2008)Polysaccharides-based nanoparticles as drug delivery systems Adv Drug Deliv Rev 60 1650-62

[8] Wolverton SE(2005)Chitosan-based particles as controlled drug delivery systems Drug Deliv 12 41-57

[9] Remlinger K(2002)Preparation and characterization of chitosan microparticles intended for controlled drug delivery Int J Pharm 249 165-74

[10] Baschant U(2001)Chitosan nanoparticles as delivery systems for doxorubicin J Control Release 73 255-67